Back to Journals » Drug Design, Development and Therapy » Volume 13

Original Research

A first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 (FAS-associated factor 1 inhibitor), a drug for Parkinson’s disease, in healthy volunteers

       
Total article views   HTML views PDF downloads Totals
11,705 Dovepress* 9,999+ 1,267 11,266
PubMed Central* 1,706 383 2,089
Totals 11,705 1,650 13,355
*Since 29 March 2019
Total mentioned Facebook Delicious Reddit Twitter Others
4 0 0 0 1 3

View citations on PubMed Central and Google Scholar